Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Centre National De La Recherche Scientifique

Assistance Publique-Hopitaux De Paris

Sorbonne Université

Université D'angers

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Francine Jotereau

Yannick Guilloux

Thierry R Boon-Falleur

Sophie Lucas

Vincent Brichard

Emmanuelle Godefroy

Harry Sokol

Frédéric Altare

Elisabeth Diez

Guillaume Sarrabayrouse

Agnès Aubry

The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4CD8ααphenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of-specific cells among CD4CD8ααT lymphocytes, from a blood sample and without needing to assess theirspecificity. T lymphocytes with a CD4CD8ααCCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease ofis particularly an inflammatory bowel disease (IBD), such as Crohn's disease.

Diagnosis, prognosis and treatment of a disease related to a decrease of

Peptides derived from MMP-2 metalloproteinase that form T cell epitopes when presented by MHC Class I molecules. Anti-tumor therapy using these peptides.

Peptides derived from the protein MMP-2, and the use thereof in antitumoral immunotherapy

New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.

Methods for determining expression of NAG tumor rejection antigen

Isolated nucleic acid molecules, peptides which form complexes with MHC

Growing community of inventors

Nantes, France

Francine Jotereau